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Abstract 
Sexual maturation of human cells in ovaries and prostate is linked to the biochemical 
cascade initiated by the activation of cell receptors through the binding of Gonadotropin 
Releasing Hormone (GnRH). The GnRH receptors (GnRHR) are part of the rhodopsin 
G-protein-coupled receptor (GPCR) family and consist of seven trans–membrane 
helical domains connected via extra– and intra–cellular segments. The GnRH–GnRHR 
complex has been implicated in various forms of prostate and ovarian cancer. The lack 
of any structural data about the GnRH receptor impedes the design of antagonists for 
use in cancer treatment. The aim of the study is to devise a model of GnRHR to be used 
further for the design of improved peptide / non-peptide GnRH analogues and, to our 
knowledge provide new structural information regarding the extracellular loop 2 
(ECL2) that acts a regulator of ligand entry to GnRHR. The common structural 
characteristics, of the members of the rhodopsin family of GPCRs, have been employed 
for the construction of a homology model for GnRHR. Structural information from the 
human β2–adrenergic receptor, as well as rhodopsins have been used in order to create 
a theoretical model for GnRHR. Furthermore, molecular dynamics (MD) simulations 
have been employed for the refinement of the model and to explore the impact of the 
bilayer membrane in GnRHR conformation.  
 
Keywords: Gonadotropin releasing hormone (GnRH); homology model; GnRH 
receptor; molecular dynamics; GPCR 
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I.  Introduction 
 The reproductive function and sexual maturation of human cells is regulated by 
hormones such as Gonadotropin-Releasing Hormone (GnRH) or Luteinizing–
hormone–releasing hormone (LHRH).[1] GnRH is a decapeptide isolated from 
hypothalamic cells.[2] Contrary to other hormones, GnRH is released in pulses with 
frequencies varying from ~30 min to 120 min.[3] The hormone initiates a biochemical 
process by interacting with the Gonadotropin-Releasing Hormone Receptor (GnRHR) 
on the surface of cells. The activated biochemical pathway leads to the release of the 
Luteinizing Hormone (LH) and the Follicle–Stimulating Hormone (FSH).[1, 4, 5] 
Three isoforms of GnRH have been identified in vertebrates that contain conserved 
residues in the N– and C–terminal ends (Figure 1A).[6] GnRH isoforms I and II have 
been identified in most vertebrate species,[7] with GnRH I presenting the most diverse 
sequence.[8] The conserved residues of GnRH have been proposed to affect the binding 
of the peptide to GnRHR and the receptor’s activation, while the variable residues in 
positions 5–8 have been linked to the function and ligand selectivity.[9-11] The 
suggested mode of action for GnRH involves distinct active conformations of GnRHR 
induced by the interactions with the GnRH isoforms. Furthermore, there is a very tight 
link between GnRH and GnRHR with the hormone regulating GnRHR expression via 
a negative feedback loop.[12]  
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Figure 1: (A) The amino acid sequences of the three natural isoforms of GnRH, with 
the conserved residues coloured red and (B) schematic representation of GnRHR, 
showing the TM helical structures connected via extracellular (ECL) and intracellular 
(ICL) loops. Residues coloured green show increased binding/potency, red present 
reduced binding/potency and yellow have no effect (adapted from GPCR database: 
http://gpcrdb.org/).[13] 
 
 GnRH receptors are part of the rhodopsin family of G-Protein Coupled Receptors 
(GPCRs) and present in three subtypes (namely GnRHR I, II and III), similarly to 
GnRH. Studies have shown that the receptors from mammalian species present more 
than 80% residue similarity.[14-16] At the same time non–mammalian GnRHRs 
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present less similarity (~45%) with their mammalian counterparts.[17-19] The 
differentiation in the sequence, points to the divergence in the evolution of GnRHR in 
mammals. This observation is further supported by the loss of the C–terminal domain 
in GnRHR I as well as in the mammalian GnRHR II.[20] In human cells, GnRHR II 
expression has been silenced despite the conservation of GnRH II across species.[21] 
This phenomenon could be attributed to the possibility of GnRHR I to be activated by 
different GnRH isoforms. There are studies reporting that antagonists and GnRH II 
induce antiproliferative effects[22, 23] while GnRH III exhibits similar activity in 
apoptotic prostate cancer cells, both via GnRHR I activation.[22] 
 The rhodopsin family of GPCRs is composed of seven helical trans–membrane 
(TM) domains connected via extracellular (ECL) and intracellular (ICL) loops (Figure 
1B). The TM domains of GnRHR have been implicated in conformational changes 
relevant for signal transduction, while the ECL domains have been involved in substrate 
binding.[24] Rhodopsin was the first GPCR structure solved by X–ray 
crystallography,[25] but several members of the family, including GnRH receptors, 
have no experimentally derived structure. Thus, any conformational and functional 
information for GnRHR is derived from modeling techniques and site–directed 
mutagenesis experimental data. The proposed theoretical models are based on both 
common residues and structural characteristics of GPCRs. The seven TM helical 
domains create a bundle that penetrates the cell membrane, adopting a similar 
conformation in most members of the rhodopsin family. The greatest variation is mostly 
observed in the ECL and ICL domains. In the rhodopsin family, residues Asp2.50 (in 
TM2) and Asn7.49 (in TM7) are conserved, but in GnRHR the positioning of these 
residues is inverted to Asn2.50(87) and Asp7.49(319).[26] This suggests a complementary 
role for these amino acids in the conformation and activation of receptor.[26] 
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Experimental data have suggest that residues on TM1 [Arg1.35(38)], TM2 
[Asp2.61(98)/Asn2.65(102)], TM3 [Lys3.32(121)], TM5 [Asn5.40(212)], TM6 [Tyr6.58(290)] and 
TM7 [Asp7.31(302)] are involved in the binding of the hairpin (β–turn) conformation of 
GnRH I.[27-29]  
 The close association of GnRH and GnRHR with various types of cancer 
highlights the importance of the receptor in new potential cancer treatments. Thus, the 
development of a valid homology model for the receptor may lead to a better 
understanding of its function. The application of theoretical approaches for the study of 
GnRHR and its interactions with GnRH will provide valuable information for the 
development of new and improved peptide and/or non-peptide mimetics of GnRH. 
 
II. Methods 
II.1 GnRH Receptor Homology model 
 The amino acid sequence of GnRH receptor I in FASTA format was employed 
as the search template for the construction of the model. The homology modeling 
process was performed with MODELLERv9.17 software,[30] as implemented in the 
PyMOL software package.[31] The crystal structures of human β2–adrenergic receptor 
(PDB code: 2rh1),[32] bovine (PDB code: 3dqb)[33] and squid (PDB code: 3ayn)[34] 
rhodopsins were implemented in the homology model process. Despite the low 
sequence similarity observed in the members of the rhodopsin family, it has been 
suggested that the seven TM helices share a similar orientation between the members 
of the family.[27, 28, 35] The structural similarities combined with conserved residues 
in the TM domains make possible the use of rhodopsin as a template for model 
building.[27, 28, 35] The residue sequences of the template proteins were aligned with 
the GnRHR I using the SALIGN function of MODELLER. Subsequently, the 
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homology mode was built based in the multiple sequence alignment result. The 
information regarding the presence of disulfide bonds (Cys14–Cys200 and Cys114–
Cys196) have been incorporated in the construction of the model. Additionally, we took 
into account the presence of the potential salt bridge between residues Lys3.32(121) and 
Glu2.53(90).[36] 
Loop modeling and refining. Most of the intracellular (ICL) and extracellular (ECL) 
loops of the receptor are small in size, 4-8 amino acids long (Figure 1B). Additionally, 
there are no information regarding their functionality in the binding of GnRH and the 
activation of the receptor. Thus, loops ICL1–3, ECL1 and ECL3 were not considered 
for loop modeling/refinement. On the other hand, the SuperLooper2 web server 
(http://proteinformatics.charite.de/ngl-tools/sl2/start.php)[37] has been implemented 
for the modeling of ECL2 (Figure 1B) which has a length of 22 amino acids. The pdb 
file of the constructed GnRHR I model was uploaded in the web server and the sequence 
of the loop was introduced in two segments, segment A (Ile177-Cys196) and segment B 
(Cys196-His207). This step was introduced in order not to change the position of Cys196 
that forms a disulfide bridge with Cys114. Superlooper2 searches a database of more 
than 100,000 crystal structures and employs a geometric fingerprint matching method 
to evaluate the fitness of the modeled loop. The best candidate loop models are ranked 
based on sequence similarity, steric clashes and structural information. The models with 
the highest similarity and the lowest number of clashes were selected for ECL2 
modeling. 
II.2 Model Refinement  
 The homology models, with the refined ECL2 domain, were subjected to energy 
minimization with the AMBER14 software.[38] The parameters for GnRH receptor I 
were constructed with the ff14SB forcefield.[39] The total charge of the system was 
8 
 
neutralized by the addition of fifteen Cl– ions. The minimization process was performed 
in implicit solvent over 6 consecutive steps with the addition of restraints on the 
movement of atoms. The initial restraint constant was defined at 10.0 kcal mol–1 Å–2 
and was subsequently reduced by 2 after each step. Every step of the minimization 
process involved 100 iterations (20 steps of steepest descent and 80 steps of conjugate 
gradient optimization). 
II.3 Molecular Dynamics Simulations 
 The minimized homology model was subjected to all–atom molecular dynamic 
simulation. Since GnRH receptor is a trans–membrane protein the molecule was placed 
in a pre–equilibrated membrane to simulate its natural environment. 
Membrane building. The pre–equilibrated membrane was built using the CHARMM–
GUI membrane builder web tool (http://www.charmm-
gui.org/?doc=input/membrane).[40] The particular web–tool allows the construction of 
the bilayer around the protein. The option of aligning the first principal axis along the 
Z axis was chosen for the positioning of the GnRHR. The bilayer composition of SDPC: 
SDPE: Cholesterol (a 2:2:1 mixture) was based on the work of Grossfield et.al. 
(2008)[41] on the molecule of rhodopsin. Since the AMBER14 lipid force field [42] 
does not support SD lipids, the composition of the bilayer was a 2:2:1 mixture of POPC: 
POPE: Cholesterol (total number of 125 residues per layer). 
MD simulation set up. The ff14SB forcefield[39] was implemented for the construction 
of GnRHR parameters, while the lipid parameters where constructed with the lipid14 
forcefield.[42] The parameters for the cholesterol molecule were obtained from Madej 
et.al. (2015).[43] The total charge of the system (GnRHR incorporated in the lipid 
membrane) was neutralized with the addition of 4 K+ and 19 Cl– ions, since the partial 
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in a rectangular box with dimensions 107.059x 106.295x 91.705 Å and the TIP3P water 
model[44] was used to solvate the system. The system was subsequently minimized in 
two steps; during the first step (5000 iterations of steepest descent followed by 20000 
iterations of conjugate gradient) the lipids and the receptor were restrained with a force 
constant of 10 kcal mol–1 Å–2.  The following step involved the minimization of the 
whole system (5000 iterations of steepest descent followed by 45000 iterations of 
conjugate gradient) with a restraint of 10 kcal mol–1 Å–2 on GnRHR. Following 
minimization, the system was heated to 310 K over a total of 500 ps, with weak 
positional restraints (force constant 10.0 kcal mol–1 Å–2) placed on the GnRHR and the 
membrane lipids, in two steps: (a) the increase of the temperature from 0 to 100 K over 
100 ps and (b) the increase of the temperature from 100 K to 310 K (on increments of 
50 K) over 400 ps under constant volume conditions. The heating was followed by a 
density equilibration (constant pressure) phase for 5 ns with weak positional restraints 
(force constant 5.0 kcal mol–1 Å–2) placed on the GnRHR. Finally, an equilibration 
simulation run was performed for 100 ns under the NVT ensemble with the GnRH 
receptor held in position with a force constant of 5.0 kcal mol–1 Å–2. The restraints were 
removed from GnRHR during the MD simulation production run. Two independent 
MD simulation runs (seeds) of 350 and 125 ns, respectively for a total time of 475 ns 
were carried out for the GnRHR–membrane model. 
Trajectory and Clustering analysis. All analyses (e.g. rmsd, clustering calculations and 
hydrogen bond interactions), were performed using the cpptraj module [45] of the 
AMBER14. The clustering analysis was based on the hierarchical approach [46] with 
the RMSD employed as the distance metric (cutoff 2.5 Å). All graphics were designed 
with UCSF Chimera 1.11.2.[47] 
 
10 
 
 
III. Results and Discussion 
III.1 Homology model 
 The initial models for the receptor were based on the crystal structures of human 
β2–adrenergic receptor, bovine and squid rhodopsins. For comparison reasons four 
homology models were built, the three based on the individual proteins while the fourth 
model was constructed on a combination of structural features form the three proteins 
(Figure S1). The different models of the receptor were superimposed on the Cα, N and 
C backbone atoms in order to verify the positioning of conserved residues such as 
Asn2.50(87), Asp2.61(98), Asn2.65(102), Lys3.32(121) and Asp7.49(319) (Figure S1A). The models 
based on human β2–adrenergic receptor (Figure S1A, orange) and on the combined of 
all crystal structures (Figure S1A, blue) position the specific residues with orientation 
inside the 7TM helical bundle. Furthermore, the positioning of residues Asn2.50(87) and 
Asp7.49(319) is inside the helical bundle with the side chains pointing towards each other 
(Figure S1A). The particular orientation has been proposed to stabilize the 
conformation of GnRHR via the formation of a water–mediated bridge between the 
residues.[26, 48] In the models based on bovine and squid rhodopsin (Figure S1A, gold 
and green, respectively) the positioning of these residues is towards the outside of the 
helical bundle (Figure S1A, dotted lines). This suggests that the models based on the 
two rhodopsins (bovine and squid) may not incorporate important functional and 
conformational characteristics reported for members of this GPCR family. Another 
aspect observed in the homology model of GnRHR I based on the bovine rhodopsin is 
the conformation of TM7 helix (Figure 2B, gold). The software models TM7 helix with 
a kink at right angles (93.02°) between backbone atoms C [Leu7.43(314)], Cα [Asn7.44(315)] 
and Cα [Pro7.45(316)] (Figure S1B) in contrast to the other models that represent helix 
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TM7 with no kink at its lower portion (Figure S1A). Thus, the model based on the 3dqb 
does not offer a good representation for the conformation of the particular helix. This 
mis-representation causes a shift in the position of Asp7.49(319) (Figure S1A) preventing 
the formation of the water bridge essential for the conformational stability of GnRHR 
I.[48] 
 Additionally, a comparison was performed between the proposed model (Figure 
S1A, blue) and homology models reported in the GPCR database (http://gpcrdb.org/, 
Figure 2A).[13] The homology models reported in the GPCR database are based on the 
crystal structures of the mouse active μ–opioid receptor (PDB code: 5c1m),[49] the 
human active OX2–orexin receptor (PDB code: 4s0v)[50] and the chimeric serotonin 
receptor (PDB code: 4iaq).[51] The comparison of the different models of GnRHR I 
suggests a close agreement despite the different templates. Residues Asn2.50(87) and 
Asp7.49(319) present their side chains inside the helical bundle cavity (Figure 2A) with 
small variations in their orientations (Figure 2A). Proteins in the rhodopsin family do 
not share great sequence similarity but they share common structural characteristics. 
Thus, it is safe to assume that the positioning of the particular side chain residues may 
vary between the different models as well as between the different template crystal 
structures. 
ECL2 loop refining and modeling. ECL2 is highly variable in the different members of 
the family and the crystal structure of rhodopsin cannot be implemented as a 
template.[25, 27] In rhodopsin, ECL2 adopts an anti–parallel β–hairpin conformation 
which is not conserved in other members of the family. ECL2 flanks the trans–
membrane domains TM4 and TM5 (Figure 2B) and has been implicated in ligand 
binding and receptor activation.[52-55] It has been proposed that ECL2 acts as a “lid” 
on top of the binding pocket of GPCRs and thus regulates ligand entry into the 
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receptor.[53, 54] Despite the presence of the disulfide bridge between residues Cys114, 
located on top of the TM3 domain, and Cys196 (Figure 2B) the loop retains its freedom 
of movement. The disulfide bond between the two Cys residues has also been proposed 
to drive the proper folding and activation of GPCRs.[54, 55] The only feature conserved 
in most members of the rhodopsin family is the Cys–Cys bond which positions the loop 
on top of the TM–bundle further supporting the role of ECL2 as a regulator for ligand 
entry and binding.[27] Employing this feature in the loop modeling (see Methods 
section II.1) the 177-196 segment (Figure 2B, blue) was modeled on the human 
Angtiotensin receptor (PDB code: 4zud) and the 197-207 segment (Figure 2B, 
magenta) was modeled on a segment from cytochrome C (PDB code: 3cxh). The 
sequence similarity with the respective GnRHR segments was approximately 45% for 
both templates. Despite not having the highest similarity index compared to other 
templates, the template structures presented the lowest number of steric clashes with 
the rest of the residues of GnRH receptor and thus were selected as templates for the 
model of the ECL2 domain.  
 
Figure 2: (A) Comparison of homology models for GnRHR I TM2, TM3 and TM7 
helical domains, showing the side chain orientation for residues Asn2.50(87), Asp2.61(98), 
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Asn2.65(102), Lys3.32(121) and Asp7.49(319) represented as sticks. The color scheme of the 
different models is: blue for the model on all three crystal structures, pink for 5c1m, 
light grey for 4s0v, and orange for 4iaq and (B) ECL2 modeled conformation showing 
the anchor residues (Ile177 and His207) as sticks and the disulfide bridge between Cys114 
(in TM3 domain) and Cys196.  
 
III.2 Model Refinement  
 The development of a homology model, based on three different members of the 
rhodopsin family (described in Section II.2), poses certain challenges. Most members 
of the rhodopsin family of receptors share common structural features but lack great 
residue homology.[26, 48, 53] Thus, the development of a model may lead to steric 
clashes observed between residues that may not have been modeled correctly. This 
feature may be more prominent in the ECL and ICL domains since they show the 
greatest variability.[26] The best way to alleviate this potential problem is the 
refinement of the model with consecutive cycles of minimization employing positional 
restraints that are gradually abolished. In Figure 3A and Table S1 we present the 
changes in the potential energy (Epot) of the proposed model, of GnRHR alone, over six 
cycles of minimization. The small number of steps (100) per cycle along with the 
imposition of restraints –that were gradually abolished (Table S1)– was employed in 
order for the minimized structure to retain the basic features of the model, while 
resolving any potential steric clashes. The graph (Figure 3A) presents the decrease in 
Epot over each cycle, with a very steep drop in the potential energy at the beginning of 
the first cycle and a further sharp drop at the start of the second cycle (Figure 3, Table 
S1). The largest deviation during the refinement process is observed on the ECL2 
domain (Figure 3B). The RMSD between the ECL2 domain at the beginning of the 
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minimization process (Figure 3B, white) and at the end (Figure 3B, dark purple) is 0.5 
Å compared to the RMSD of the whole GnRHR (0.2 Å) and that of the other ECL and 
ICL domains. The greatest difference in ECL2 is mainly focused on the positioning of 
residues Val192, Ser194, His199, Trp206, His207 and Phe210 (Figure 3B). The side chains of 
these residue deviate from their original positions and this change is most prominent of 
the conformation of the rings for His199, Trp206, His207 and Phe210. 
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Figure 3: (A) Graph of Epot for the GnRHR homology model after six sequential 
minimization cycles and (B) the comparison of the ECL2 domain at the beginning 
(white) and the end (dark purple) of the refinement process. 
 
III.3 Molecular Dynamics  
 The construction of the homology model provides us with information regarding 
common structural features of members of the same family of proteins. Despite these 
similarities, the localization and function of these proteins may affect their 
conformation. Thus, MD simulations offer the tools to analyze the effect of the 
environment. In our case the homology model embedded in a bilayer, was subjected to 
two independent MD simulation runs of 350 and 125 ns, respectively (total time: 475 
ns). Since GnRHR is present in various different cell types, there is no extensive 
information on its membrane environment. In order to explore the effect of the 
membrane in GnRHR conformation, we employed a membrane model developed for 
rhodopsin MD simulations.[41] The choice of the particular membrane model was 
based on the homology similarity of rhodopsin with GnRHR (both members of class A 
GPCRs) and the lipid parameters employed in the AMBER14 force field (see also 
section II.3 in Methods). The analysis of the RMSD values, for the Cα atoms (Figure 
S2A) shows that the movement of the Cα atoms of GnRHR deviates rapidly during the 
first few 5 ns of the simulation time compared to the reference structure (homology 
model). After this initial deviation, the Cα atoms of the receptor do not present great 
fluctuations during the rest of the simulation (Figure S2) and the RMS values are 
centered on 5 Å. This small deviation in the receptor movement can be attributed to the 
close packing imposed by the bilayer. Since the majority of GnRHR residues are found 
in the TM domains, their movement would be restricted by the close proximity of the 
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lipids in the bilayer. The changes in the atomic positional fluctuations of the residues 
are depicted in Figure 4, where the residues located in the trans-membrane helices 
present smaller deviation from their original conformation compared to the ECL and 
ICL domains. 
 
 
Figure 4: Positional atomic fluctuations (in Å) for the backbone atoms (N, C, O and 
Cα) of the GnRHR residues compared to the initial homology model over the MD 
simulation time. The dotted lines define the positions of the residues for the TM 
domains of the receptor. 
 
 Furthermore, the RMSD values for the backbone atoms of the TM domains were 
calculated in reference to the initial conformation of the homology model (Figure 6, 
Table S2). The results show small changes in the backbone conformation for TM 
domains 1–4 (Figure 5). The residues in these helices do not deviate extensively from 
their initial conformation with the maximum RMSD values reaching 2.96 Å for TM1 
(Table S2) and the mean values for the four helices being 1.97 Å (for TM1), 1.34 Å (for 
TM2), 1.61 Å (for TM3) and 2.61 Å (for TM4) (see also Table S2). This small change 
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is mirrored in the positional fluctuations of the residues (Figure 4), where the mean 
atomic fluctuation for the residues in TM1 through TM4 is less than 2.0 Å (Table S2). 
The largest conformational changes during the MD simulation are focused on the 
residues of TM5 (Figure 5). For the first 50 ns there are extensive conformational 
changes in the TM5 reaching values of up to 5 Å before the changes reach equilibrium 
around 4.5 Å (Figure 5). Despite a small jump in the RMS between 180 and 200 ns, no 
major conformational changes are reported during the simulation time. These changes 
could be attributed to the large number of residues comprising the TM5 helix, as well 
as to the anchor segments of the domain (Figures 1 and 4). TM5 helix is located between 
the ECL2 and ICL3 domains. Both these domains are more mobile and thus the TM5 
helix residues anchored to both ECL2 and ICL3 show higher positional fluctuations 
(Figure 4) with a mean atomic fluctuation of 2.01 Å. This observation may also account 
for the greater conformational changes observed for the TM6 helix (Figure 5). The 
anchoring segment of TM6 with ICL3 –which is highly mobile– (Figures 1 and 4), 
presents higher positional fluctuations that may affect the conformations of the helical 
domain leading to the increased RMSD values (mean RMSD 3.5 Å, Table S2). Finally, 
the TM7 domain shows smaller conformational changes over time (Figure 5) compared 
to domains TM5 and TM6. The average RMSD value is 2.90 Å (Table S2) with the 
maximum value of 4.00 Å being reached at 90 ns (Figure 5) before dropping and 
stabilizing at the average of 3.85 Å until the end of the simulation. This small 
conformational change is also mirrored on the positional fluctuations (Figure 4) with 
the mean for all the residues of the TM7 helix being 1.63 Å (Table S2). As expected, 
the atomic fluctuations of the ICL and ECL domains are higher than those observed for 
the TM domains (Figure 4) due to lack of any secondary structural features. Moreover, 
their positioning is outside the membrane bilayer and thus no restrictions, due to close 
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packing, are imposed on the residues. ICL1 and ICL3, along with the N-terminal 
domain, present the highest fluctuations despite their smaller size compared to ECL2 
(Figure 4). The low fluctuations of the ECL2 domain could be attributed to the 
secondary structure elements observed (α–helix, Figure 3) and the presence of the 
disulfide bridge between Cys114 and Cys196. 
 
 
Figure 5: RMS deviations for the backbone atoms (N, C, O and Cα) of the residues 
comprising the seven TM domains compared to the initial conformation of the 
homology model over the MD simulation time. The differences of the RMS values over 
time present the conformational changes observed in the TM domains.  
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Clustering analysis. The clustering analysis performed on the MD simulations 
revealed the presence of five clusters for GnRHR (Table S3, Figure S2B). The dominant 
cluster 1 is present for 37% of the simulation time, cluster 2 is present for 24% of the 
time, while the other three clusters account for approximately the rest of the MD 
simulation time. The superimposition of the different clusters with the initial homology 
model shows the structural differences in the various TM domains observed over the 
course of the simulation (Figure 6). The comparison of the MD results reveals the small 
changes in domains TM1–4 (Figure 6A), while the greatest conformational changes are 
observed mostly on TM helices 5 and 6 (Figure 6B). As depicted in Figure 6B (grey, 
bottom), the TM5 and TM6 conformations deviate from the initial structure (Figure 6B, 
magenta). This result is in accordance with the RMS deviations observed for the two 
helices (Figure 5). Furthermore, it is important to note that the particular segments of 
the two helices are the anchor segments with the ICL3 domain connecting the two, 
which presents large atomic positional fluctuations (Figure 4).  
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Figure 6: Superimposition of the different MD clusters (white) with the initial 
homology model (magenta): (A) TM domains 1 to 4 and (B) TM domains 5 to 7.  
 
 The clustering analysis revealed also the conformational changes observed for the 
amino acids important in GnRH binding and receptor activation –TM2 
[Asp2.61(98)/Asn2.50(87)], TM3 [Lys3.32(121)] and TM7 [Asp7.49(319)]– (Figure 7). As 
expected, MD simulations create a dynamic picture of the molecule recording the 
different conformational changes over time. In this case, we report the changes in the 
distances between TM2 [Asp2.61(98)]–TM3 [Lys3.32(121)] and TM2 [Asn2.50(87)]–TM7 
[Asp7.49(319)] (Figure 7). The distance between the Cα atoms of Asp2.61(98) and Lys3.32(121) 
is decreasing over the course of the MD production run (Figure 7A, right panel). This 
suggests a movement of the two helices towards each other in comparison to their initial 
position based on the homology model (distance of 10.3 Å). This movement could be 
readily explained by the effect of the lipid molecules that are in close proximity to the 
TM helices. The close packing imposed by the bilayer may lead to the movement of 
amino acid towards each other and affect not only the conformational aspects of the 
GnRHR. This is in accordance with the results of the clustering analysis that shows 
small conformational changes in TM2 helix between the homology model and the MD 
simulations (Figure 6A, magenta and grey, respectively). On the other hand, the 
distance between helices TM2 and TM7 remains relatively unchanged during the MD 
simulation compared to the homology model with the distances being 8.4 and 7.9 Å, 
respectively (Figure 7B, right panel). These observations suggest that helix TM2 may 
play an important role GnRH binding by its induced conformational change on the 
specific region (Figures 6A and 7A). 
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Figure 7: Distances between the Cα atoms of the dominant conformation (white) 
derived from the MD simulation with the initial homology model (magenta) for 
residues (A) Asp2.61(98) –Lys3.32(121) and (B) Asn2.50(87)–Asp7.49(319).  In the right panel we 
present the graphs depicting the changes of the respective distances over time (for the 
Cα atoms of the residues) during the MD simulation. 
 While the homology model provides the necessary structural information based 
on the different templates, it does not offer information regarding the effects of the 
membrane in its conformation. In this section we presented the dynamic features of 
conserved structural elements (see Figures 4, 5 and 7) of GnRHR. We record no major 
changes in the behavior of TM1–TM4 and TM7 (Figure 5), while a decrease in the 
distance between Asp2.61(98) –Lys3.32(121) is observed (Figure 7A). At the same time the 
orientation of residues Lys3.32(121) and Glu2.53(90) is not affected greatly during the MD 
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simulation (Figure S2B), a finding that is in agreement with other conformational 
studies of the receptor and other GPCRs.[36, 56]  
III.4 Conclusions 
 The homology model, reported in this study, was based on the conformational 
information derived from three different members of the rhodopsin family (namely the 
human β2–adrenergic receptor, the bovine and squid rhodopsins). The developed model 
shows great similarities in comparison with other models reported in the GPCR 
database (http://gpcrdb.org/, Figures 2 and S1). The structural similarities between our 
homology model and those already present in the GPCR database show that despite the 
differences in the residue sequence of the GPCRs, the conformational aspects required 
for the function of these receptors remain intact in the different members and affect the 
tertiary structure of the receptors. Additionally, MD simulations have been 
implemented in order to monitor the dynamic behavior of the molecule as it is 
embedded in a lipid bilayer. The analysis revealed that there are conformational 
changes in the domains of GnRHR (Figure 5) as well as in certain areas of the receptor 
that have been implicated in GnRH binding (Figure 7A). Most of these changes are 
expected since the close packing of the receptor inside the membrane may affect the 
movement of the different domains. But, the clustering analysis (Figure 6) showed that 
there are no great conformational changes in the receptor compared to the initial 
structure of the homology model. Even the orientation of residues does not change 
extensively and remains close to their initial position. The results reported in this paper 
corroborate the findings of different studies on the conformational aspects of class A 
GPCRs. Moreover, the comparison between our model and other homology models 
reported in the GPCR database (http://gpcrdb.org/, Figure 2A), [13] show that the main 
structural features of GnRHR are conserved despite the different templates employed. 
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This type of information can prove valuable in the understanding of GnRHR function 
and binding mode. Additionally, the homology model, along with the MD simulations, 
will provide the necessary template and stereochemical information for the design of 
new GnRHR potential agonist and antagonist peptide and non-peptide mimetic 
analogues.  
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